Evidence map›Paper›PMID 24427537›Full record

ArticleInterface focus2013

Antisense peptide nucleic acid-functionalized cationic nanocomplex for in vivo mRNA detection.

Yuefei Shen, Ritu Shrestha, Aida Ibricevic, Sean P Gunsten, Michael J Welch, Karen L Wooley, Steven L Brody, John-Stephen A Taylor, Yongjian Liu

Open access · bronzeAbstract read
In one paragraph

Article in Interface focus, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Multifunctional Delivery Systems for Peptide Nucleic Acids.Pharmaceuticals (Basel, Switzerland) · 2020
    Review
  5. Review
  6. Review
  7. Article
  8. Nanotechnology for delivery of peptide nucleic acids (PNAs).Journal of controlled release : official journal of the Controlled Release Society · 2016
    Review
  9. Chemical science · 2015
    Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Yuefei ShenDepartment of Chemistry , Washington University , St Louis, MO 63130 , USA.
Ritu ShresthaDepartment of Chemistry and Chemical Engineering , Texas A&M University , PO Box 30012, College Station, TX 77842-3012 , USA.
Aida IbricevicDepartment of Medicine , Washington University , St Louis, MO 63110 , USA.
Sean P GunstenDepartment of Medicine , Washington University , St Louis, MO 63110 , USA.
Michael J WelchDepartment of Radiology , Washington University , St Louis, MO 63110 , USA.
Karen L WooleyDepartment of Chemistry and Chemical Engineering , Texas A&M University , PO Box 30012, College Station, TX 77842-3012 , USA.
Steven L BrodyDepartment of Medicine , Washington University , St Louis, MO 63110 , USA ; Department of Radiology , Washington University , St Louis, MO 63110 , USA.
John-Stephen A TaylorDepartment of Chemistry , Washington University , St Louis, MO 63130 , USA.
Yongjian LiuDepartment of Radiology , Washington University , St Louis, MO 63110 , USA.
University of Washington · USCollege Station Medical Center · USWashington University in St. Louis · USUniversity of Washington Applied Physics Laboratory · US

Funding

NHLBI NIH HHS HHSN268201000046C
6 · The paper itself

Abstract

Acute lung injury (ALI) is a complex syndrome with many aetiologies, resulting in the upregulation of inflammatory mediators in the host, followed by dyspnoea, hypoxemia and pulmonary oedema. A central mediator is inducible nitric oxide synthase (iNOS) that drives the production of NO and continued inflammation. Thus, it is useful to have diagnostic and therapeutic agents for targeting iNOS expression. One general approach is to target the precursor iNOS mRNA with antisense nucleic acids. Peptide nucleic acids (PNAs) have many advantages that make them an ideal platform for development of antisense theranostic agents. Their membrane impermeability, however, limits biological applications. Here, we report the preparation of an iNOS imaging probe through electrostatic complexation between a radiolabelled antisense PNA-YR9 · oligodeoxynucleotide (ODN) hybrid and a cationic shell-cross-linked knedel-like nanoparticle (cSCK). The Y (tyrosine) residue was used for (123)I radiolabelling, whereas the R9 (arginine9) peptide was included to facilitate cell exit of untargeted PNA. Complete binding of the antisense PNA-YR9 · ODN hybrid to the cSCK was achieved at an 8 : 1 cSCK amine to ODN phosphate (N/P) ratio by a gel retardation assay. The antisense PNA-YR9 · ODN · cSCK nanocomplexes efficiently entered RAW264.7 cells, whereas the PNA-YR9 · ODN alone was not taken up. Low concentrations of (123)I-labelled antisense PNA-YR9 · ODN complexed with cSCK showed significantly higher retention of radioactivity when iNOS was induced in lipopolysaccharide+interferon-γ-activated RAW264.7 cells when compared with a mismatched PNA. Moreover, statistically, greater retention of radioactivity from the antisense complex was also observed in vivo in an iNOS-induced mouse lung after intratracheal administration of the nanocomplexes. This study demonstrates the specificity and sensitivity by which the radiolabelled nanocomplexes can detect iNOS mRNA in vitro and in vivo and their potential for early diagnosis of ALI.

Indexed as

acute lung injurycationic nanoparticlesinducible nitric oxide synthasepeptide nucleic acidradiolabellingtargeting

Identifiers

PMID24427537
PMCPMC3638413
OpenAlexW2112911550

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.